Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Misty Wheelock

Nurse Practitioner, Adult Health Saint Louis, MO Nurse Practitioner

NPI 1073700217 CMS profile 10978704

10050 Kennerly Rd Ste 2400, Saint Louis, MO 63128

Open in the dashboard

General payments

$9,217

516 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Misty Wheelock of Saint Louis, MO is reported in the CMS Open Payments database as having received $9,217 across 516 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Nurse Practitioner, Adult Health profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,564 71
2024 General $1,136 51
2023 General $1,401 93
2022 General $2,401 137
2021 General $2,715 164

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Misty Wheelock
  • Nurse Practitioner, Adult Health median
  • Middle half of Nurse Practitioner, Adult Health
  • National median

In program year 2025, general payments to Misty Wheelock were reported at $1,564. Among 12,696 Nurse Practitioner, Adult Health profiles paid that year, the median was $184 and the middle half received between $59 and $580.

Show as a table
Year Misty Wheelock Nurse Practitioner, Adult Health median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,715 $138 $43–$438 $132
2022 $2,401 $165 $54–$494 $149
2023 $1,401 $178 $61–$549 $160
2024 $1,136 $186 $62–$575 $164
2025 $1,564 $184 $59–$580 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $3,320 147 payments
  2. Salix Pharmaceuticals, a division of Bausch Health US, LLC $846 62 payments
  3. Abbott Laboratories $535 40 payments
  4. Amgen Inc. $396 19 payments
  5. Biohaven Pharmaceutical Holding Company Ltd. $287 34 payments
  6. Novartis Pharmaceuticals Corporation $267 12 payments
  7. Biohaven Pharmaceuticals, Inc. $266 25 payments
  8. Lilly USA, LLC $256 15 payments
  9. Pfizer Inc. $254 23 payments
  10. Collegium Pharmaceutical, Inc. $247 16 payments
  11. Other $2,544 123 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,217 516 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $2,644 113 payments
  2. RELISTOR $846 62 payments
  3. NURTEC ODT Primary Care $553 59 payments
  4. QULIPTA $527 28 payments
  5. AIMOVIG $396 19 payments
  6. Proclaim IPG $207 15 payments
  7. NURTEC ODT Pain $197 20 payments
  8. XTAMPZA $192 12 payments
  9. EMGALITY $170 11 payments
  10. REYVOW $170 11 payments
  11. Other $4,676 254 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

192

Median for Nurse Practitioner: 389

Drug cost

$36,485

Median for Nurse Practitioner: $21,885

Branded share of claims

14.1%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Nurtec Odt Rimegepant Sulfate Brand 16 $19,834
Ubrelvy Ubrogepant Brand 11 $11,984
Diclofenac Sodium Generic 12 $3,314
Gabapentin Generic 45 $578
Ibuprofen Generic 19 $176
Baclofen Generic 26 $152
Duloxetine Hcl Generic 11 $140
Tizanidine Hcl Generic 11 $122
Cyclobenzaprine Hcl Generic 16 $87
Topiramate Generic 14 $65

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 3 billing codes

Paid by Medicare

$3,357

Medicare's payments for the services billed

Medicare patients

37

Average age 72

Services billed

65

21 women, 16 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 65%
Cancer 62%
Arthritis 62%
Atrial fibrillation 54%
Depression 54%
Heart failure 51%
COPD 51%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 50 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
LIBTAYO
  • Regeneron Healthcare Solutions, Inc. $87
$87 — —
ENHERTU
  • AstraZeneca Pharmaceuticals LP $44
  • Daiichi Sankyo Inc. $28
$72 — —
FRUZAQLA
  • Takeda Pharmaceuticals U.S.A., Inc. $71
$71 — —
EPKINLY
  • AbbVie, Inc. $31
  • Genmab U.S., Inc. $18
$48 — —
SCEMBLIX
  • Novartis Pharmaceuticals Corporation $42
$42 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 50 with Patron

Records

516 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Adult Health in Missouri

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record